AbSci Announces Completion of $125 Million Crossover Financing to Advance AI-Powered Synthetic Biology Drug Creation Platform | Absci Uncategorized Archives - Absci

Round was co-led by Casdin Capital and Redmile Group
Fidelity Management & Research Company LLC, D1 Capital Partners, and Perceptive Advisors are among the new investors

VANCOUVER, Wash., March 23, 2021 /PRNewswire/ — AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a $125 million crossover financing. The round was co-led by existing investors Casdin Capital and Redmile Group, with participation from new investors Fidelity Management and Research Company LLC, D1 Capital Partners, Perceptive Advisors, aMoon Edge, and Irving Investors, as well as other existing investors including ArrowMark Partners.

“We are thrilled to have such a well-respected group of life sciences investors who share our vision of transforming the way drugs are created,” said Sean McClain, founder and CEO of AbSci. “As we unlock access to novel biologies and therapeutic modalities, and work with our partners to create exciting new medicines, we are continuing to innovate and expand the scope of what we can accomplish and the impact we can have to improve human health.”

Eli Casdin, Chief Investment Officer and Founder of Casdin Capital, commented, “In the short time since the Series E, AbSci has made tremendous progress, advancing drug discovery technologies, acquiring Denovium, a state-of-the-art deep learning platform for protein engineering, and announcing partnerships with both Merck and Astellas. We look forward to seeing AbSci continue to execute on its vision.”

Proceeds will support AbSci’s continued growth, including research and development activities and other strategic investments. Key areas of focus are integration and training of the Denovium EngineTM deep learning artificial intelligence platform AbSci acquired in January 2021, and ongoing expansion of core discovery capabilities including non-standard amino acid technologies.

“We believe that AbSci has a truly differentiated approach, which includes a fully integrated technology for simultaneously discovering new biologics and the cell lines to manufacture them,” said Dan Sundheim, Chief Investment Officer and Founder of D1 Capital Partners. “We are excited to support the company as it advances programs with partners and participates in creating better medicines for patients.”

About AbSci

AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that reinvents the biopharmaceutical drug discovery process. Our patented SoluPro® E. coli expression system and Protein Printing™ platform, informed by our deep learning Denovium Engine™, enable simultaneous creation of novel biotherapeutic drugs and the cell lines to manufacture them in a single efficient process. In one workflow, we select cell lines producing drug candidates with optimal target potency and affinity as well as high-titer expression. Starting with a known drug sequence or with a target for de novo discovery, our approach dramatically reduces biopharma discovery and development timelines from years to weeks by generating a GMP-ready manufacturing cell line for each asset. We specialize in next-generation biologics built on complex protein scaffolds, which have proven challenging for others to produce. With more than a dozen partnerships in place with top pharma and industry leaders, our collaborations include projects for drugs and drug candidates that range across multiple protein types and therapeutic functionality. For more information, please visit https://www.absci.com.

VANCOUVER, Wash., – February 22, 2021 – AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and potential discovery collaborations with Merck Research Laboratories.

AbSci founder and CEO Sean McClain said, “It has been terrific to work with Merck on many levels. We are pleased to be able to add value and bring solutions to tough problems. With the success of our initial projects, as well as this investment from Merck GHI, we have set in place a foundation upon which to build out a broad and mutually beneficial partnership with Merck. Everyone we have worked with at Merck shares the goal of helping the most patients with the best medicines as quickly as possible.”

“AbSci falls into a special investment allocation towards what we see as ‘Next Horizon’ technologies that have the potential to disrupt the biopharmaceutical industry,” said Prem Tumkosit, Managing Director of Merck GHI. “AbSci’s technologies may enable discovery and development of exciting new biotherapeutics that could meaningfully impact human health in the years to come.”

This partnership aligns with AbSci’s research and development activities. Key areas of focus are integration and training of the Denovium Engine deep learning artificial intelligence platform AbSci acquired in January 2021, and ongoing expansion of core discovery capabilities including non-standard amino acid technologies. AbSci’s Protein PrintingTM platform technology enables de novo biologic drug creation in a matter of weeks. It is scaffold-agnostic; by screening for initial hits in the desired full-length scaffold format, and in the cell line that will be used for manufacturing, AbSci dramatically accelerates preclinical timelines and offers avenues to create designer next-generation biologics that would not otherwise be possible.

About Merck Global Health Innovation Fund

Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy. This investment strategy connects innovative companies with complementary technologies to develop integrated healthcare solutions. Merck GHI has $500M under management and provides growth capital to emerging healthcare technology companies worldwide while leveraging the vast R&D-based, global resources of Merck. With a vision that data will be the currency in healthcare, Merck GHI invests broadly in digital health. Merck GHI invests in platform companies with proven technologies or business models where Merck’s expertise and perspectives can accelerate revenue growth and enhance value creation.  Since late 2010, Merck GHI has made over 50 investments in Digital Health companies. www.merckghifund.com

About AbSci

AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that reinvents the biopharmaceutical drug discovery process. Our patented SoluPro® E. coli expression system and Protein Printing™ platform, informed by our deep learning Denovium Engine™, enable simultaneous creation of novel biotherapeutic drugs and the cell lines to manufacture them in a single efficient process. In one workflow, we select cell lines producing drug candidates with optimal target potency and affinity as well as high-titer expression. Starting with a known drug sequence or with a target for de novo discovery, our approach dramatically reduces biopharma discovery and development timelines from years to weeks by generating a GMP-ready manufacturing cell line for each asset. We specialize in next-generation biologics built on complex protein scaffolds, which have proven challenging for others to produce. With more than a dozen partnerships in place with top pharma and industry leaders, our collaborations include projects for drugs and drug candidates that range across multiple protein types and therapeutic functionality. For more information, please visit https://www.absci.com.

-Second molecule addressed under the collaboration agreement, first to exploit AbSci discovery technologies-

 VANCOUVER, Wash., February 3, 2021 /PRNewswire/ — AbSci, a pioneering synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics, today announced that it has partnered with Xyphos Biosciences, an Astellas Company, to screen and identify a variant of Xyphos’ MicAbody™ lead candidate for optimal manufacturing cell line development. The MicAbody is a bispecific antibody-like adaptor molecule critical for Xyphos’ program in immuno-oncology. The agreement between the companies calls for AbSci to employ its Protein PrintingTM technology to inform selection of optimal variant MicAbody candidates and a custom E. coli SoluPro® production strain for further potential development and cGMP manufacturing.

AbSci founder & CEO Sean McClain commented, “We are pleased to expand our relationship with Xyphos to include AbSci’s discovery capabilities, and we look forward to continuing our partnership as Xyphos and Astellas advance development of molecules manufactured using our Protein Printing platform.”

Financial terms of the agreement were not disclosed.

About AbSci

AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that reinvents the biopharmaceutical drug discovery process. Our patented SoluPro® E. coli expression system and Protein Printing™ platform, informed by our deep learning Denovium Engine™, enable simultaneous creation of novel biotherapeutic drugs and the cell lines to manufacture them in a single efficient process. In one workflow, we select cell lines producing drug candidates with optimal target potency and affinity as well as high-titer expression. Starting with a known drug sequence or with a target for novel drug discovery, our approach dramatically reduces biopharma discovery and development timelines from years to weeks by generating a GMP-ready manufacturing cell line for each asset. We specialize in next-generation biologics built on complex protein scaffolds, which have proven challenging for others to produce. With more than a dozen partnerships in place with top pharma and industry leaders, our collaborations include projects for 28 drugs and drug candidates that range across multiple protein types and therapeutic functionality. For more information, please visit https://www.absci.com.

About Xyphos Biosciences, Inc., an Astellas Company.

Xyphos Biosciences, Inc., located at South San Francisco, Calif., is a wholly owned subsidiary of Astellas featuring ACCELTM technology, a technology platform for CAR (chimeric antigen receptor) – immune cell therapy. ACCELTM technology is based on the fusion of receptor-expressing immune cells such as natural killer (NK) cells and T cells (convertibleCAR® cells) with antibodies that recognize cancer antigens, the target of attack. The technology is based on the administration of an antibody-ligand fusion protein (MicAbody), which is a fusion of an antibody and a ligand protein. By replacing or using multiple MicAbodies according to the characteristics of the cancer cells to be attacked, convertibleCAR® cells can recognize different cancer antigens or multiple cancer antigens and attack various cancer cells. Xyphos Biosciences was launched in 2017, and the Company was acquired by Astellas Pharma in December of 2019. For more information about the Company, please visit www.xyphosinc.com.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

AbSci Contact
Kate Corcoran, Ph.D.
[email protected]
360-949-1041

Integration of Denovium Engine™ with AbSci’s Protein Printing™ Platform to enable creation of novel biotherapeutics and manufacturing cell lines with the click of a button

 Vancouver, Wash., January 12, 2021 – AbSci, a leading synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics, today announced the acquisition of Denovium, Inc., an artificial intelligence (AI) deep learning company. AbSci will integrate the Denovium Engine into its drug discovery and manufacturing cell line development capabilities and expects to realize near term synergies using AI deep learning to better predict relevant variants and cell line characteristics for each new project. With continued application and further training of the Denovium Engine, AbSci’s vision is to make in silico biologic drug discovery and cell line development a reality. This will enable next-generation therapies to make it to market at unprecedented speeds. Terms of the acquisition are not being disclosed.

“This acquisition represents the perfect synergy of groundbreaking synthetic biology and cutting-edge deep learning AI to create in silico predictive protein drug design and cell line development capabilities with the potential to completely change the paradigm of biopharmaceutical discovery and development,” said Sean McClain, founder and CEO of AbSci. “Incorporating deep learning will allow us to explore all possible protein sequences in silico, including those that Nature’s evolutionary trajectory has yet to consider, to identify drug candidates with optimal therapeutic properties and manufacturability. Combining that design power with our proprietary data from our Protein Printing platform, AbSci can create a new gold standard for drug discovery and cell line development for next-generation biologics while at the same time allowing for creation of novel biologies previously unattainable.”

The Denovium Engine is a multidimensional deep learning model built to interpret, categorize, predict, and evolve function and behavior of proteins. The platform incorporates far more than sequence and structure relationships, having been trained on functional data from more than 100 million proteins and across over 700,000 descriptive parameters. AbSci intends to further train the Denovium Engine on its proprietary internally-generated multidimensional protein characterization datasets that include elements of protein functionality, expression, and manufacturability.

“Training the Denovium Engine on the volumes of high-quality protein function and manufacturability data being generated by AbSci’s Protein Printing platform allows our platform to reach its full potential of de novo design of manufacturable proteins having desirable functionalities,” said Toby Richardson, Ph.D., founder and CEO of Denovium. “We expect that the platform will be able to design proteins by predicting not only the optimal sequence for each therapeutic candidate, but also the conditions for manufacturing, to enable production of therapeutic proteins that were previously not possible.”

About Denovium Inc.

Denovium is an artificial intelligence company pioneering novel AI methods to accelerate innovation in biopharma. Founded by genomics and computer science experts, Denovium is building an artificial intelligence engine (Denovium Engine™) capable of interpreting disparate biological data types to answer biology’s toughest questions. Denovium is partnering with leading biotech and pharma companies in specific areas of focus including gene discovery, protein engineering and genomic medicine.

About AbSci

AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that reinvents the biopharmaceutical drug discovery process. Our patented SoluPro® E. coli expression system and Protein Printing™ platform enable simultaneous creation of novel biotherapeutic drugs and the cell lines to manufacture them in a single efficient process. In one workflow, we select cell lines producing drug candidates with optimal target potency and affinity as well as high-titer expression. Starting with a known drug sequence or with a target for novel drug discovery, our approach dramatically reduces biopharma discovery and development timelines from years to weeks by generating a GMP-ready manufacturing cell line for each asset. We specialize in next-generation biologics built on complex protein scaffolds, which have proven challenging for others to produce. With more than a dozen partnerships in place with top pharma and industry leaders, our collaborations include projects for 28 drugs and drug candidates that range across multiple protein types and therapeutic functionality. For more information, please visit https://www.absci.com.

# # #

Media Contact
Heidi Chokeir, Ph.D.
Canale Communications
[email protected]
619-203-5391

Investor Contact
Kate Corcoran, Ph.D.
[email protected]
360-949-1041

 

VANCOUVER, Wash.Jan. 7, 2021 /PRNewswire/ — AbSci, a leading synthetic biology company enabling drug discovery and biomanufacturing of next generation biotherapeutics, today announced that Sean McClain, Founder and CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 7:25 a.m. PT / 10:25 a.m. ET.

About AbSci

AbSci is ushering in a new era of biopharmaceutical discovery and manufacturing technologies, designing and programming E. coli bacteria to produce challenging biologics at commercial scale. AbSci’s patented SoluPro(R) expression platform enables rapid and robust production of complex proteins, ranging from antibodies, antibody fragments, enzymes, hormones and peptides, to emerging novel classes of biotherapeutics. AbSci’s discovery engine and Protein Printing™ technology offer unprecedented efficiencies by enabling simultaneous optimization of drug candidate potency and affinity combined with high-titer cell line development. The system increases discovery throughput, accelerates commercial process development, reduces manufacturing costs, and increases plant capacity for biopharmaceutical partners, enabling novel biologics to advance to market and creating a new gold standard in biotherapeutic discovery and production. For more information, please visit https://www.absci.com.

SOURCE AbSci

Related Links

absci.com

See Press Release Here

Ivana Magovčević-Liebisch, Ph.D., J.D. and Karen McGinnis join AbSci Board as Independent Directors

VANCOUVER, Wash.Nov. 11, 2020 /PRNewswire/ — AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing and discovery of biotherapeutics, today announced that Ivana Magovčević-Liebisch and Karen McGinnis have joined its board as independent directors.

“We are delighted to welcome Ivana and Karen to our board of directors,” said Sean McClain, Founder and CEO of AbSci. “Eli Casdin from Casdin Capital and Amrit Nagpal from Redmile Group have also recently joined our board in connection with our Series E financing. These four new directors are joining AbSci at an exciting time as we accelerate our efforts to impact the future of biomanufacturing and drug discovery. They collectively bring tremendous strategic leadership and financial markets experience, and we look forward to their contributions as we enter into our next phase of growth.”

“I am thrilled to join the AbSci Board and am eager to contribute to the company’s mission to revolutionize biopharmaceutical discovery and manufacturing,” said Dr. Magovčević-Liebisch. “I look forward to applying my expertise to help advance this vitally important effort to enable next-generation biologics and positively impact human health.”

“AbSci is poised for significant growth and I’m incredibly excited to join their board,” said Ms. McGinnis. “Next-generation biologics has a current end market of $14 billion and is the fastest growing segment in the therapeutics market today. AbSci’s Protein PrintingTM technology has a unique opportunity to support the commercialization of next-generation biologics which have long been considered unmanufacturable, allowing biopharmaceutical companies to get the absolute best drug candidate to market.”

About Ivana Magovčević-Liebisch, Ph.D., J.D.
Magovčević-Liebisch is an accomplished pharmaceutical and biotechnology executive focused on corporate excellence and execution. She has over 20 years of senior management experience in biotechnology and pharmaceutical industry with expertise in financing, corporate partnering and M&A, clinical development, regulatory affairs, commercialization, legal and IP matters, and preparation and implementation of operating plans. She currently serves as the President and Chief Executive Officer at Vigil Neuroscience, Inc., a biotech company focused on harnessing microglia biology to treat neurodegenerative diseases.

Prior to Vigil, she was Executive Vice President, Chief Business Officer of Ipsen. Magovčević-Liebisch serves as a member of the Board of Directors of Applied Genetic Technologies Corporation (AGTC) and Aeglea BioTherapeutics. Magovčević-Liebisch is also a Trustee of the Boston Museum of Science and the Boston Ballet, and an overseer of Beth Israel Deaconess Medical Center. She holds a Ph.D. in Genetics from Harvard University and received her J.D. in High Technology law from Suffolk University Law School. She graduated from Wheaton College with a B.A. in Biology and Chemistry. In 2008 and 2019, she was the recipient of the Women Entrepreneurs in Science and Technology Leadership Award. In 2019, she was recognized as one of the 20 Fiercest Women in Life Science by FiercePharma.

About Karen McGinnis
McGinnis has over 20 years of experience in executive operational and finance roles at international public and private companies. She currently serves as the Vice President and Chief Accounting Officer of Illumina. Prior to Illumina, McGinnis served as the Chief Financial Officer and later as the Chief Executive Officer and President of Mad Catz Interactive. She has also served as the Chief Accounting Officer, Corporate Controller and Vice President of Cymer and as the Chief Accounting Officer of Insight Enterprises. McGinnis is a member of the Board of Directors of Alphatec Holdings (ATEC). She is a Certified Public Accountant and received her Bachelor of Science degree in Accounting from the University of Oklahoma.

Financing to accelerate first mover advantage of Protein Printing™ technology which enables revolutionary efficiencies in protein manufacturing

VANCOUVER, Wash.Oct. 20, 2020 /PRNewswire/ — AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing and discovery of biotherapeutics, today announced a $65 million Series E equity financing. The round was led by Casdin Capital with participation from other new investors, Redmile Group and ArrowMark Partners, and other existing investors, including Phoenix Venture Partners. Representatives of Casdin Capital and Redmile Group will join AbSci’s Board of Directors as a part of the financing.

“We believe AbSci’s Protein Printing™ technology has a unique opportunity to support the commercialization of next-generation biologics which have long been considered unmanufacturable,” said Eli Casdin, Chief Investment Officer and Founder at Casdin Capital. “In addition, AbSci’s differentiated commercial model presents a unique opportunity to share in their partners’ successes with opportunities for a revenue stream from drug development all the way through to approval and commercialization. We look forward to supporting AbSci as they execute on their vision to transform biomanufacturing and drug discovery.”

Proceeds from the financing will be used to increase production capacity, accelerate facility expansion and support research and development activities. AbSci is making protein production as simple as DNA synthesis through its revolutionary Protein Printing technology, which combines the power of E. coli SoluPro® with a cutting-edge synthetic biology platform for generation of high-diversity strain libraries and high-throughput screening assays. This technology delivers unprecedented titers with superior product quality for any biotherapeutic protein allowing biopharmaceutical companies to get the absolute best drug candidate to market.

“At AbSci, our mission is to revolutionize biopharmaceutical discovery and manufacturing using our Protein Printing technology to enable unprecedented precision and speed,” said Sean McClain, Founder and CEO of AbSci. “Our team is committed to continually innovate and push the boundaries of what is possible. We are grateful to our new and existing investors for their support of our vision and we look forward to deploying this capital to transform the future of biomanufacturing.”

About AbSci
AbSci is a leading synthetic biology company focused on redefining protein biomanufacturing. We are making protein production as simple as DNA synthesis through our revolutionary Protein Printing™ technology. AbSci enables a pathway to commercialization for biologics that otherwise wouldn’t get to market due to poor manufacturability. Our mission is to improve patients’ lives by reducing drug costs, accelerating development timelines, and enabling new biologic therapies to market. For more information, please visit https://www.absci.com.

https://www.prnewswire.com/news-releases/absci-announces-65-million-financing-led-by-casdin-capital-301155825.html

VANCOUVER, Wash.July 21, 2020 /PRNewswire/ — AbSci, a growth-stage synthetic biology company whose Protein Printing™ technology enables rapid and low-cost biomanufacturing of difficult-to-produce biotherapeutics, today announced that it has entered into an agreement to license its E. coli SoluPro® protein expression technology to Alpha Cancer Technologies for the production of Recombinant Human Alpha-fetoprotein (hAFP). hAFP is a natural human protein produced by human embryo and yolk sac during development and can be used in the treatment of various autoimmune diseases and cancers.  This license is an expansion of a previous collaboration between the parties that began last year.

Igor Sherman, CEO of Alpha Cancer Technologies comments, “AbSci has demonstrated the superiority of their SoluPro expression platform and their high throughput approach of producing very difficult to express protein. While we use a transgenic expression system for our cGMP material, many have tried using conventional expression platforms and have been unsuccessful. This is a truly enabling platform that provides an expanded commercialization pathway for ACT and will allow us to significantly expand our patent life and IP portfolio”

“Alpha fetoprotein is a very challenging molecule to express. With 16 disulfide bonds which are important for its function it has proven to be very difficult to produce in commonly used expression systems,” said Sean McClain, AbSci CEO. “By using our E. coli SoluPro® cell line and proprietary high throughput assays we were able to screen millions of genetically diverse expression solutions to find the ideal solution for Alpha Cancer Technologies”

Under the terms of the agreement AbSci will prepare the hAFP producing E. coli strain for transfer to Alpha Cancer Technologies’ CMO of choice for commercial production. Alpha Cancer Technologies will receive an exclusive license to the producing cell line and related patents from AbSci. AbSci will receive undisclosed development and sales milestones plus royalties on the annual net sales.

About AbSci
AbSci is a global leader and innovator of revolutionary biomanufacturing technologies, designing and programming cells for next-generation biopharmaceuticals. AbSci’s Protein Printing™ technology is the new gold standard in protein production, as it increases discovery throughput, accelerates development, reduces manufacturing costs, and increases plant capacity for the biopharmaceutical industry. Its patented SoluPro™ expression platform rapidly produces complex proteins, ranging from mAbs, Fabs, enzymes, hormones and peptides, to emerging novel classes of biotherapeutics. For more information, please visit https://www.absci.com.

About Alpha Cancer        
Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in immunotherapy (Inflammatory Bowel Disease, Multiple Sclerosis, Myasthenia Gravis, Hashimoto) and immuno-oncology (almost all solid and liquid tumors uniquely express the receptor for AFP). The company’s drug platforms use proprietary recombinant human alpha fetoprotein (AFP).

ACT has exclusive worldwide rights to AFP with over $115 million spent on the development of the in-licensed technology. Clinical studies of AFP have demonstrated safety in over 300 patients and established a robust Drug Master file with the FDA including manufacturing, toxicology, and human safety.  Bristol Myers Squibb owns a 14% equity interest in ACT.

For more information please visit www.alpha-cancer.com

SOURCE AbSci

Related Links

absci.com

https://www.prnewswire.com/news-releases/alpha-cancer-technologies-to-license-abscis-solupro-strain-for-the-expression-of-alpha-fetoprotein-301097227.html

[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22.4″][et_pb_row admin_label=”row” _builder_version=”3.22.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”|311px||auto||”][et_pb_column type=”4_4″ _builder_version=”3.0.47″][et_pb_text admin_label=”Text” _builder_version=”3.22.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”0px|||||”]

VANCOUVER, Washington – January 13, 2020 – AbSci, the Protein Printing™ company with a best-in-class E. coli cell line for rapid and low-cost biomanufacturing of complex biotherapeutics, today announced the completion of a $10.4M Series D financing led by KBI Biopharma and JSR Life Sciences. Existing investors Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Columbia Ventures Corporation also participated in the financing.  The financing also includes $5M in term debt. The proceeds from the financing will be used for expansion of AbSci facilities and team in order to meet commercial demand for AbSci’s technology.    

AbSci’s Protein Printing™ technology combines the power of E. coli SoluPro® with a cutting-edge synthetic biology platform for generation of high-diversity strain libraries and high-throughput screening assays to deliver unprecedented titers of complex biotherapeutic proteins with superior product quality. AbSci continues to accelerate its partnerships with industry-leading companies due to its track record providing enabling and scalable manufacturing solutions for next-generation biotherapeutics. In 2019, AbSci increased its revenue by over 800%. The Series D financing will support the company’s continued aggressive growth by increasing capacity to meet growing demand from the biopharma industry for rapid, ultra-high yield and quality production of next-generation biotherapeutics.    

In addition, AbSci and KBI Biopharma have entered into an exclusive co-marketing agreement to jointly market and promote each other’s technologies, products, and services. Under the agreement, KBI Biopharma, a leading biopharmaceutical CDMO providing fully integrated biopharmaceutical development and manufacturing services, has the exclusive right to market AbSci’s Protein Printing™ technology worldwide and is AbSci’s preferred CDMO for industrial scale-up of biologics developed using AbSci technology. This agreement will give partners a seamless path from cell line development to process optimization/scale up and cGMP manufacturing.

“We are thrilled to partner with KBI Biopharma, a premier CDMO and technology leader. This partnership allows us to better serve our partners by giving them rapid and direct line of sight to GMP manufacturing,” said Sean McClain, Founder and CEO of AbSci. “AbSci has developed a reputation for solving complex manufacturing hurdles that have stymied next-generation biotherapeutics. These molecules have proven to be extremely difficult or impossible to produce in other protein expression platforms. AbSci’s Protein Printing™ technology is uniquely suited to solve this manufacturing issue and enables pharma and biotech companies to get these truly groundbreaking therapies to the market and improve patient outcomes.” 

Tim Kelly, President and CEO of KBI Biopharma stated, “We believe that AbSci’s microbial expression technology is truly disruptive, and we are excited to deliver unique solutions to the biopharmaceutical industry via our partnership.  The next generation of biologics will be enabled only though innovation and product development expertise.  Our world class team and FDA and EMA-approved clinical and commercial microbial manufacturing facilities in Boulder, CO are ideally suited to translate AbSci’s technology into new medicines for patients in need.”

 

About AbSci

AbSci is a global leader and innovator of revolutionary biomanufacturing technologies, designing and programming cells for next-generation biopharmaceuticals. AbSci’s Protein Printing™ technology is the new gold standard in protein production, as it increases discovery throughput, accelerates development, reduces manufacturing costs, and increases plant capacity for the biopharmaceutical industry. Its patented SoluPro™ expression platform rapidly produces complex proteins, ranging from mAbs, Fabs, enzymes, hormones and peptides, to emerging novel classes of biotherapeutics. For more information, please visit https://www.absci.com.

About KBI Biopharma, Inc.

KBI Biopharma, a JSR Life Sciences company, is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 300+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), San Diego (CA), and Leuven, Belgium.

 

About JSR Life Sciences

JSR Life Sciences, LLC is committed to the advancement of human health by improving the probability of success, decreasing timelines, and increasing the efficacy of innovative therapies. Based in Sunnyvale, CA, JSR Life Sciences operates a network of manufacturing facilities, R&D labs and sales offices in key markets throughout North America, Europe and Asia-Pacific.

Contacts:

Company and Media Inquiries for KBI Biopharma and JSR Life Sciences

Missy Bindseil

Marketing Communications Manager

+1 830-237-9527

[email protected]

 

Company and Media Inquiries for AbSci

Kole Krieger
Senior Director, BD and Marketing
[email protected]


[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators. Culling from a variety of lists that recognize researchers and inventors and company leaders under those ages, here’s a list of 10 interesting researchers under the age of 40 who are already making a significant mark on the biopharma and life sciences research world.

Jason Buenrostro. Buenrostro is an assistant professor in the Department of Stem Cell and Regenerative Biology at Harvard University. He is 31 years old. Buenrostro and his colleagues invented a tool called ATAC-seq that measures open DNA regions that might be active. They have since further developed the technology to identify open DNA in a single cell, which allows scientists to pinpoint which genes are active in single cells.

Ava Carter. Carter, 28, is a PhD student at Stanford University. She was noted as one of the 30 Under 30 by Forbes for 2019. She is studying the epigenome and with her research group, has identified how DNA from each parent is used differently in human stem cells. Her research has also discovered how some animals turn their stem cells back on to regenerate tissue after injury.

Silvia Caballero. Caballero, 34, heads the multidrug-resistant organisms decolonization program at Vedanta Biosciences, based in Cambridge, Massachusetts. One of her early research findings, while working in a laboratory at Memorial Sloan-Kettering Cancer Center in New York, was to identify species of bacteria that fight multi-drug-resistant bacteria. That original research was in lab mice, but she is now leading similar work at Vedanta, hoping to find bacteria that can control the bacteria that cause the three most deadly hospital and nursing home bacterial infections.

Sean McClain. McClain, 29, is the founder and chief executive officer of AbSci, based in Vancouver, Washington. AbSci has a SoluPro protein expression platform that provides insight into protein folding and allows for a chromatography-free purification method that removes downstream processing bottlenecks. In January, AbSci inked a deal with Paris-based Sanofi.AbSci will use its E. coli manufacturing platform, SoluPro and its optimization assay system with two of Sanofi’s molecules.

Nicole Gaudelli. Gaudelli, 34, is a senior scientist at Beam Therapeutics, based in Cambridge, Massachusetts. Her title is Head of DNA Editing Platform, focused on developing new technologies related to genome editing and optimizing base editing technologies. Gene-editing technology like CRISPR can fix many genetic mistakes that cause inherited disease, but they don’t always fix, for example, when an adenine (A) should have been a guanine (G). This particular mutation is involved in several diseases, including sickle cell disease, cystic fibrosis, Parkinson’s, Alzheimer’s, and some types of cancers. Gaudelli has developed a new enzyme that can cleanly change A-T base pairs into G-C base pairs.

Luke Osborn. Osborn, 29, is a PhD candidate at Johns Hopkins University. He has developed a type of electronic skin that can be used with prosthetics to create a sense of pressure and pain. One of Forbes’ 30 Under 30 for 2019, the skin is called e-dermis, and is a fabric-and-rubber sheath implanted with sensors. The technology has been tested successfully in volunteers and the research continues to refine it.

Jeremy Puthumana. Puthumana, 26, is a researcher at the Yale University School Of Medicine. He is conducting research into novel serum and urine biomarkers for the diagnosis of acute kidney injury, chronic kidney disease, hepatorenal syndrome, and kidney transplantation. He received his BS, MS and MD all at Yale. He is also one of Forbes’ 30 Under 30 for 2019.

Sana Alajmovic. Alajmovic, 32, is the co-founder and chief executive officer of Sigrid Therapeutics, a Swedish clinical-stage biotechnology company. Sigrid Therapeutics’ lead candidate is SiPore15 to treat blood sugar levels in people at risk for diabetes. She is part of the Karolinska Innovations incubator Drive in Sweden. In addition to making Genetic Engineering & Biotechnology News’ 2019 list of “Top 10 Under 40 of 2019,” Alajmovic was named one of Sweden’s 101 Super Talents by the Swedish business magazine Veckans Affarer in 2012.

Ankit Mahadevia. Mahadevia, 38, is the co-founder, president and chief executive officer of Spero Therapeutics, based in Cambridge, Massachusetts. The company is focused on developing antibiotics for Gram-negative bacterial infections. Its lead product, SPR994, is being investigated as the first oral carbapenem antibiotic for adults for multi-drug resistant (MDR) Gram-negative infections. On June 20, 2019, the company entered into a collaboration pact with The Bill & Melinda Gates Medical Research Institute (MRI) to develop SPR720 for lung infections caused by Mycobacterium tuberculosis.

Kaitlyn Sadtler. Sadtler, 29, is a postdoctoral fellow at the Massachusetts Institute of Technology(MIT). Her research focuses on the intersection of immunology and regenerative medicine, focusing on the modulation of immune responses to promote functional tissue development. Essentially, Sadtler is attempting to develop a drug or therapy that could help the immune system regenerate tissue and to develop medical implants and ways to prevent scarring.

Source